Regeneron Pharmaceuticals vs Eli Lilly vs Novo Nordisk and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Regeneron Pharmaceuticals 4.291, Eli Lilly 19.799, Novo Nordisk 96.823, Pfizer 14.451.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Regeneron Pharmaceuticals, Eli Lilly, Novo Nordisk, Pfizer.| Metric | Regeneron Pharmaceuticals | Eli Lilly | Novo Nordisk | Pfizer |
|---|---|---|---|---|
| Market Cap | $76.02B | $1.03T | $228.21B | $142.76B |
| Revenue | $4.29B | $19.80B | $96.82B | $14.45B |
| Cost of Revenue | $71.00M | $3.58B | $13.60B | $4.73B |
| Gross Profit | $4.22B | $16.22B | $83.22B | $9.72B |
| Operating Income | $1.29B | $8.85B | $59.62B | $4.03B |
| Net Income | $1.30B | $7.40B | $48.56B | $2.69B |
| R&D Expense | $1.53B | $3.51B | $10.28B | $2.63B |
| Earnings Per Share | $12.2 | $8.26 | $10.91 | $0.47 |
| Gross Margin | 98.3% | 81.9% | 86.0% | 67.3% |
| Operating Margin | 30.1% | 44.7% | 61.6% | 27.9% |
| Net Profit Margin | 30.2% | 37.4% | 50.1% | 18.6% |
| Free Cash Flow | $573.00M | $3.01B | $12.04B | $2.18B |
| Cumulative Free Cash Flow | $32.06B | $101.90B | $654.97B | $356.40B |
| Operating Cash Flow | $813.00M | $5.33B | $24.08B | $2.62B |
| Cash & Equivalents | $2.46B | $5.28B | $21.13B | $1.70B |